Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Realty & auto in limelight
Fri, 23 Jan 01:30 pm

Indian share markets continued to trade firm in the post-noon trading session. Barring consumer durable and IT, all the sectoral indices are trading in the green. Realty & auto are the biggest gainers today.

BSE-Sensex is up 246 points and NSE-Nifty is trading 64 points up. BSE Mid Cap is trading down marginally and BSE Small Cap index is trading down by 0.5%. The rupee is trading at 61.48 to the US dollar.

Majority of the FMCG stocks are trading weak led by Procter & Gamble Hygiene & Healthcare and Lakshmi Energy. Jyothy laboratories and Hindustan Unilever are among the few stocks trading in the red. As per a leading financial daily, the Income Tax Department has ordered several multinational companies mostly in the FMCG space to pay taxes on advertisement, marketing and sales promotional expenses (AMP) expenses incurred over and above the industry average. The tax department's argument in this case is that if an Indian subsidiary of a foreign multinational spends more than the average AMP expenses then the additional amount is going towards brand promotion and in turn creating marketing intangibles. Therefore the additional amount should be chargeable to tax under transfer pricing. Based on this additional ad-spend, companies like Hindustan Unilever, Procter & Gamble, L'Oreal, LG and Maruti Suzuki face tax demands. This move has been challenged in the Delhi High Court and the decision is expected in the next ten days. Apart from this multinational companies have also approached the Income Tax tribunal in this regard.

Domestic pharma stocks are trading mixed with Dishman Pharma and Wockhardt being the biggest gainers. However, Biocon and Glenmark Pharma are among the major losers. As per a leading financial daily, the US Food & Drug Administration (USFDA) has issued a ban on products from the manufacturing facilty of IPCA Laboratories in Ratlam, Madhya Pradesh. The company's facility received regulatory observations in July last year following inspection by USFDA. As a result the company had voluntarily suspended the shipments of the active pharmaceutical ingredient (API) from the facility to the US. With the situation remaining unresolved, the import alert has been issued by USFDA. IPCA has clarified that four API's namely Hydroxychloroquine Sulphate, Propanolol Hydrochloride, Trimethoprim and Ondansetron have been excluded from the import alert.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty & auto in limelight". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.